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Abstract
This is a case of a 62-year-old male, presented with UGI symptoms for a short period, upon biopsy it turned out to be a neuroendocrine 
tumor with hepatic metastasis and locoregional nodes.
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INTRODUCTION
A unique group of malignant growths – 
NEUROENDOCRINE TUMORS, best known for their 
ability to secrete bioactive peptides, which may cause 
symptoms such as flushing and diarrhea [1]. NETs 
classified as clinically symptomatic (functioning) or 
silent (nonfunctioning); both types frequently synthesize 
more than one peptide, although often these are not 
associated with specific syndromes [2]. As they being 
uncommon and may be nonspecific in their prentation, 
delays in diagnosis are frequent.
CASE PRESENTATION
A 62-year-old male known comorbid, presented in 
Oncology OPD with complaints of abdominal pain, 
nausea, vomiting and weight loss since 2 months. On 
examination, he had mild to moderate hepatomegaly 
almost 4 finger breadths from the costal margin with no 
tenderness, and the rest of the abdomen was soft with 
no distention or so. The rest of the systemic examination 
was normal. Investigations have been done to make the 
diagnosis.
RADIOLOGICAL FINDINGS-CT ABDOMEN WITH 
CONTRAST
The liver was enlarged with multiple hypodense areas 
(see Fig. 1). One of them was at anterior superior 
sub-segment viii with a lesion of 5.1x 2.1 cm with no 
intrahepatic biliary duct dilatation. There was abdominal 
lymphadenopathy with enlarged lymph nodes in the 
peripancreatic and mesenteric region-largest: 3.2 cm. 
There was minimal thickening of the pyloric end of the 
stomach. 
BONE SCAN
Negative for any metastasis but arthritic changes in the 
left knee joint.
ENDOSCOPIC FINDINGS
The patient had undergone EGD and Biopsy in which 
at the stomach there was a large irregular mass at the 
body of the stomach extending from lesser curvature to 
the pylorus (see Fig. 2). Multiple biopsies were taken.
HISTOPATHOLOGY DETAILS
The gastric growth biopsy showed individual cells with 
round nuclei with coarse chromatin and pale cytoplasm. 
The Immuno Histo Chemistry showing CK AE1/ AE 3 
and SYNAPTOPHYSIN POSI-TIVE WITH Ki 67 of 10-
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Fig. (1): Enlarged liver with marked pointers as hypodense lesions 
in liver.
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15% (see Figs. 3 & 4) Favoring neuroendocrine tumor 
– grade II.
TUMOR BOARD DISCUSSION
In the multidisciplinary meeting involving Medical 
Oncologists, General Surgeons, Histo-pathologists and 
Radiologists case was discussed and options of surgery 
versus systemic therapy were discussed. Surgeon Dr. 
Nadeem Khurshaidi raised the issue of the possibility 
of adeno carcinoma also as that will completely change 
the prognosis. The histopathologist Dr. Hanna Naqvi 
responded by saying that it’s very unlikely because 
Synaptophysin is strongly positive. Dr. Nadeem 
Khurshaidi said in a patient with multiple liver metastases 
and lymphadenopathy the indication for resection of the 
primary tumor is only if the patient is symptomatic with 
an ob-struction or GI bleed and the patient doesn’t have 
any of these. Dr. Misbah from radiology ad-vised to get 
DOTATATE SCAN done to further clarify disease activity 
and extent. Dr. Naila Zahid asked for the role of TACE 
but the consensus was because of the extent of liver 
metastases its benefit is questionable. Therefore Board 
decided to get a Dotatate scan and urinary 5 HIAA and 
then start Somatostatin analogues.
SURGEON’S PERSPECTIVE 
Literature is scant regarding management protocols for 
Gastric Neuroendocrine tumors with liver metastasis. 
These are a set of rare tumors that secrete neuroendocrine 
hormones and have the potential of metastasis. Upon 
presentation, almost 40 to 70 percent of tumors have 
already metastasized to the liver. Liver Metastasis 
accompanies about 28.3–77.0% of pancreatic NET and 
67–91% of small intestine NET at initial presentation [3], 
which is an important prognostic marker.
Surgical resection remains the mainstay of therapy 
in such tumors even with liver metastasis. In patients 
receiving complete surgical resection, the 5-year survival 
rate may reach up to 80 percent in contrast to the non-
surgical approach which is only 30 percent [4].
Based on liver metastasis finding, the distribution is as 
follows in groups [4, 5]:
I. Type I: for liver metastases localized in one lobe or two 
adjacent segments, standard anatomical resection 
can achieve the en bloc resection of the lesion. Such 
cases of GEP-NET with liver metastasis account for 
about 20–25%.
II. Type II: the metastatic lesions are mainly distributed 
in the right or left lobe of the liver; however, small 
satellites still exist in another lobe. This type accounts 
for about 10–15%. Clinically this type is mainly 
treated with multidisciplinary strategies including 
surgical resection (the mainstream treatment) and 
ablation therapy.
Fig. (2): Large irregular mass at the body of stomach, extending from 
lesser curvature to pylorus.
Fig. (3): Nests of tumor cells with rounded nuclei showing coarse 
chromatin and pale cytoplasm.
Fig. (4): The immunohistochemistry showing CK AE1/ AE 3 and 
synaptophysin positive with Ki 67 of 10-15%.
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III. Type III: the metastases are diffusely distributed in 
the left and right lobes of the liver and cannot be 
treated with surgery. This type accounts for about 
60–70%.
Generally, the surgical treatment of GEP-NET with liver 
metastasis must meet the following conditions: (i) with 
resectable well-differentiated (G1/G2) liver metastases 
and the predicted peri-operative mortality rate of 
<5%; (ii) without right cardiac dysfunction; (iii) without 
unresectable lymph node metastasis or extraperitoneal 
metastases; and (iv) without diffuse or unresectable 
peritoneal metastasis [6].
In our current case, the patient already has gNEN (G2) 
with multiple liver metastases at first presentation. In 
this scenario, we may consider it to be a type III liver 
metastases. In such a case according to case reports 
in the literature, as no randomized trial is available 
a treatment strategy with somatostatin analogues 
and ablation therapy may be considered fol-lowed by 
surgery as palliative resection may still have a role in 
such cases. However, the prognosis in these cases is 
guarded despite the best efforts. 
ONCOLOGIST PERSPECTIVE
Gastric NETs consist of a complex disease that includes 
different subtypes with distinct management and 
prognosis. Poor prognosis factors are lesion ≥2 cm; 
deep submucosa invasion or beyond (at least 24% are 
metastatic); Ki-67 ≥3%; vascular invasion; a low degree 
of structural differentiation; presence of atypia and/or 
necrosis. There are four types of gastric neuroendo-
crine tumors and management varies accordingly.
Type I
It comprises 70-80% of gastric NET and is associated 
with autoimmune chronic atrophic gastritis destroying 
the gastric parietal cell, and subsequent achlorhydria, 
which in turn results in hypergastrinemia leading to 
ECL cells hyperplasia. The typical endoscopic finding is 
multiple reddish polyps. The proliferation marker MKI67 
is typically expressed in less than 2% of the tumor 
cells. Patients usually have hypergastrinemia and B12 
deficiency [7]. It has a good prognosis and endoscopic 
resection is sufficient treatment [8]. Netazepide (YF476) 
is a gastrin receptor antagonist. YF476 has been reported 
to cause tumor regression in Type I gastric NET [9].
Type II
7% of gastric NET are type II. It is associated with 
Zollinger Ellison syndrome resulting in hyper-gastrinemia 
and hyperchlorhydria. Endoscopy shows normal or 
hypertrophic gastric mucosa. The proliferation marker 
MKI67 is expressed in < 2% of the tumor cells. Usually, 
the tumor is near the head of the pancreas, between 
the second and third part of the duodenum or near 
the junction of the cystic duct with a common hepatic 
duct. It has a very little chance of metastases alt-hough 
slightly more aggressive than type1. Treatment consists 
of resection of gastrinoma and endoscopic resection of 
gastric polyp if any [10]. In patients with multiple tumors 
that can’t be resected endoscopically, Somatostatin 
analogue octreotide can be used and results in a marked 
decrease in plasma gastrin levels with subsequent tumor 
regression [11].
Type III
This is the sporadic type and is 14% to 25% of gastric 
NET. It is associated with normal Gastrin level. 
Endoscopy shows a single lesion usually greater than 
1 cm in normal gastric mucosa. More than 2% of tumor 
cells express the proliferation marker MKI67. This type 
has a high propensity to metastasize and is associated 
with worse 5-year survival of 75 to 80 % compared with 
90 to 95% for type I tumors. Rarely carcinoid syndrome 
can be the presenting symptom especially in patients 
with liver metastases.
Type IV
Type IV GNET is an uncommon tumor, and usually is 
single, large, poorly differentiated, and highly malignant; 
it is typically accompanied by vascular invasion and 
metastases, has high levels of MKI67 (> 30) and has an 
extremely poor prognosis with mean survivals of 6.5 to 
14.9 months. The mainstay of treatment is aggressive 
surgery followed by chemotherapy [12]. The common-
est site of metastases of neuroendocrine tumors is the 
liver. In a Swedish study, 82% of patients with metastatic 
Neuroendocrine tumors had liver metastasis and the 
commonest source was the small intestine. The risk of 
metastasis was highest if the primary was in the small 
intestine or pancreatic hepatobiliary tract, whereas it 
was lower with appendiceal and rectal NET [13]. 
Prognostic factors in patients with the metastatic 
disease include disease burden, the presence of 
distant extrahepatic metastases, race, and older age. 
Biochemical characterization of the tumor can help 
in further characterization of the tumor and future 
monitoring of response to treatment. 
In general 24- hour urine or plasma HIAA should be 
checked whereas in patients with gastric NET serum 
gastrin level should be checked, and in pancreatic 
NETs VIP, serum Insulin and serum Glucagon should be 
checked. The “gold standard” for imaging any individual 
suspected of NET dis-ease is Gallium 68-Dotatoc 
(68Ga) PET-CT. It can show evidence of both primary 
and secondary disease with high specificity [14]. In 
patients with metastatic disease, it is important to find 
the primary to avoid side effects related to primary i.e. 
obstruction, bleeding etc. 
Metastatic neuroendocrine tumor, the treatment of 
metastatic NET is multimodality. Since even metastatic 
NET usually has an indolent course the goal of treatment 
is usually control of symptoms and maintain quality of 
life rather than cure. It can be divided into systemic 
and locoregional which intern can be surgical or non-
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surgical. Systemic treatment can also be divided into 
two tiers: symptomatic control and control of tumor 
growth. Somatostatin analogues play an important role 
in controlling symptoms [15]. Octreotide and lanreotide 
have shown similar efficacy in terms of carcinoid 
syndrome palliation, with symptom control rates usually 
ranging between 45 and 75%. In case of worsening of 
symptoms before the next due dose frequency of drug 
ad-ministration can be increased or an extra dose of 
short-acting octreotide may be effective. In patients 
with refractory carcinoid syndrome telotristat ethyl 
Serotonis synthesis inhibitor as-sessed in two double-
blind, placebo-controlled, phase III TELESTAR [16] 
and TELECAST trials at 250 or 500 mg significantly 
reduced bowel movement frequency and 5-HIAA levels. 
Telotristat is generally well-tolerated, is associated with 
mild nausea and hepatic enzyme elevations. 
Somatostatin analogues are very effective in slowing 
the disease progression also. In phase III PROMID trial 
monthly Octreotide LAR 30mg resulted in statistically 
and clinically significant improvement in median time 
to progression from 6 months on the placebo arm 
to 14.3 months on the octreotide arm (hazard ratio 
0.34; p = 0.000072) [17]. Similar results were found 
in another double-blind, placebo-controlled, phase III 
CLARINET trial of 204 patients with lanreotide depot 
at 120 mg/4 weeks or placebo with 96% of patients 
having radiographically stable disease. Lanreotide 
was associated with a significant prolongation of 
progression-free survival (PFS) when com-pared with 
placebo (median not reached versus 18 months, after 
a median study drug exposure of 24 months; hazard 
ratio 0.47, p <0.001) [18]. Although both the trials had 
only patients with Ki-67 index of less than 10%, likely, 
both octreotide and lanreotide are also active in well-
differentiated, SSTR-positive tumors whose proliferative 
activity exceeds 10%. 
Radiolabeled somatostatin analogs are a form of 
radiolabeled systemic therapy. Phase III NET-TER-1 
study of 177Lu-DOTATATE versus high-dose octreotide 
LAR (60 mg/month) in 229 patients with advanced, 
octreoscan-positive midgut NETs who progressed on 
standard-dose octreotide LAR showed that 177Lu-
DOTATATE therapy resulted in a 79% reduction in risk of 
progression or death compared with high-dose octreotide 
(p < 0.0001; hazard ratio 0.21; 95% CI, 0.13–0.33) at 
14 months follow up. The median PFS was not reached 
in the lutetium arm versus 8.4 months in the control 
arm, and consistent benefit across major subgroups 
was shown by subgroup analysis. The overall response 
rate (ORR) observed in patients treated with PRRT 
was significantly higher than in patients who received 
octreotide (18 versus 3%, respectively; p < 0.0004) 
[19]. Although the short time effects including nausea, 
vomiting and myelosuppression are manageable its 
limitations are the long-term toxicities including renal 
failure and leukemia/myelodysplastic syn-dromes 
(MDS). The long term incidence of acute leukemia/
MDS after PRRT is ~2%. M-Tor inhibitor Everolimus 
previously approved for Pancreatic NET was found to 
have a statistically significant benefit in PFS in NETs of 
lung and gastrointestinal origin in double-blind, phase III 
RADIANT-4 study from 3.9 months on the placebo arm 
to 11 months on the everolimus arm (hazard ratio 0.48; p 
= 0.00001) leading to FDA for the treatment of advanced 
NETs, regardless of the primary site [20].  Side effects of 
the mTOR inhibitor include hyperglycemia, cytopenias, 
oral ulcers, rash, diarrhea, and atypical infections, 
including potentially serious pneumonitis. 
Antiangiogenic agents have been found to have activity 
in pancreatic NETS. There is an ongoing trial with 
sunitinib in gastrointestinal NETs. IFN has shown both 
antisecretory and antiproliferative activities in GEP-
NETs. In one study addition of IFN to octreotide showed 
improvement in symptom control in 49% of patients 
with suboptimally controlled carcinoid syndrome [21]. 
In patients with poorly differentiated neuroendocrine 
carcinomas chemotherapy should be considered. Usually 
like small cell lung cancer there is a rapid response to 
platinum-based regimens, but remissions are usually 
short-lived. Thus far, no studies have compared platinum-
based regimens versus temozolomide- or streptozocin-
containing protocols in patients with poorly differentiated 
GEP-NETs. Combination of CDDP plus irinotecan (CPT-
11) has an overall response rate of 75% and progression-
free survival of 212 d [22]. Chemotherapy is found to be 
effective in, low-to-intermediate-grade pNETs who have 
bulky, rapidly progressive, and/or symptomatic disease 
but minimal activity in gastrointestinal NET.
There are ongoing trials with PD1 monoclonal antibodies. 
Pancreatic NETs have a worse prognosis than GINETs 
and respond differently to anticancer agents, with most 
agents demonstrating higher response rates among 
patients with pancreatic NETs than those with GINETs. 
Further-more, survival is better in small intestinal primary 
compared to colon primary. 
Locoregional Treatment in patients with metastatic 
NETs, because of longer median survival as compared 
to other malignancies resection of the primary should 
be considered if the primary site is causing symptoms. 
Moreover in patients with a resectable primary and liver 
metastases but no extrahepatic disease, diffuse bilobar 
involvement, or compromised liver function surgical 
resection of the primary, as well as metastasectomy, 
should be performed. On the contrary, it’s unclear if 
the resection of asymptomatic primary sites in patients 
with unresectable metastatic disease is of any benefit. 
Surgical resection of liver metastases not only provides 
symptomatic control, in some studies is found to be 
associated with a survival benefit (50 to 60 % 10-year 
survival) but this is proportional to the extent of resection 
of the tumor burden [23]. Whereas for patients who 
have multifocal and bilateral disease needing major 
hepatectomy with a risk of major compromise in function 
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of the remaining liver, ablation is most often used as 
an adjunct to surgical resection to allow local treatment 
of all disease which is associated with 50% response 
rate [24]. Surgery is contraindicated in metastatic poorly 
differentiated neuroendocrine carcinoma because of its 
poor prognosis.
CONCLUSION
In metastatic neuroendocrine tumors with isolated liver 
metastases resection of the primary tumor and liver 
metastases can provide symptom control and has been 
associated with favorable long-term survival, with 10-
year survival rates approaching 50 to 60 percent in some 
series. In patients with unresectable disease, treatment 
decision depends on symptoms, tumor characteristics 
and performance status of the patient. In patients with 
low-grade tumors Somatostatin analogues not only can 
control the symptoms but also improve PFS. Whereas 
in rapidly progressive poorly differentiated tumors earlier 
use of chemotherapy and radiolabeled somatostatin 
analogues is warranted. 
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